Cumberland Pharmaceuticals (CPIX) EPS (Weighted Average and Diluted) (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 17 years of filings, most recently posting -$0.22 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.22, down 375.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.49 (down 96.0% YoY), and the FY2025 annual result was -$0.19, up 58.7% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.22 for Q1 2026 at Cumberland Pharmaceuticals, down from -$0.09 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.08 in Q1 2025 to a low of -$0.44 in Q4 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.09 (2022), against an average of -$0.1.
• Across the five-year window, EPS (Weighted Average and Diluted) surged 166.67% in 2023 and plunged 1500.0% in 2024, its largest moves.
• Cumberland Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.17 in 2022, then slumped by 158.82% to -$0.44 in 2023, then jumped by 68.18% to -$0.14 in 2024, then soared by 35.71% to -$0.09 in 2025, then plunged by 144.44% to -$0.22 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.22 (Q1 2026), -$0.09 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.